Clinical Trial Update: ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial [Phase 1]

View source ↗

Summary

Phase 1 trial update for ERAS-801 in IDH-wildtype glioblastoma or astrocytoma with EGFR amplification or mutation; enrolling currently.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-wildtype
• Glioblastoma Idh-wildtype

Drugs mentioned

• ERAS-801

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: IDH Wildtype Glioblastoma, Recurrent Astrocytoma | Phase 1 | Status: RECRUITING